1. Role of the endocannabinoid and endovanilloid systems in an animal model of schizophrenia-related emotional processing/cognitive deficit.
- Author
-
Almeida V, Levin R, Peres FF, Suiama MA, Vendramini AM, Santos CM, Silva ND, Zuardi AW, Hallak JEC, Crippa JA, and Abílio VC
- Subjects
- Affective Symptoms chemically induced, Animals, Arachidonic Acids agonists, Arachidonic Acids antagonists & inhibitors, Arachidonic Acids metabolism, Arachidonic Acids pharmacology, Arachidonic Acids therapeutic use, Cannabinoid Receptor Agonists pharmacology, Cannabinoid Receptor Agonists therapeutic use, Cognitive Dysfunction chemically induced, Endocannabinoids agonists, Endocannabinoids antagonists & inhibitors, Male, Polyunsaturated Alkamides agonists, Polyunsaturated Alkamides antagonists & inhibitors, Polyunsaturated Alkamides metabolism, Rats, Rats, Inbred SHR, Rats, Wistar, Schizophrenia chemically induced, Schizophrenia prevention & control, Affective Symptoms metabolism, Cannabinoid Receptor Modulators metabolism, Cognitive Dysfunction metabolism, Disease Models, Animal, Endocannabinoids metabolism, Schizophrenia metabolism
- Abstract
Studies suggest that the endocannabinoid and endovanilloid systems are implicated in the pathophysiology of schizophrenia. The Spontaneously Hypertensive Rats (SHR) strain displays impaired contextual fear conditioning (CFC) attenuated by antipsychotic drugs and worsened by pro-psychotic manipulations. Therefore, SHR strain is used to study emotional processing/associative learning impairments associated with schizophrenia and effects of potential antipsychotic drugs. Here, we evaluated the expression of CB
1 and TRPV1 receptors in some brain regions related to the pathophysiology of schizophrenia. We also assessed the effects of drugs that act on the endocannabinoid/endovanilloid systems on the CFC task in SHRs and control animals (Wistar rats - WRs). The following drugs were used: AM404 (anandamide uptake/metabolism inhibitor), WIN55-212,2 (non-selective CB1 agonist), capsaicin (TRPV1 agonist), and capsazepine (TRPV1 antagonist). SHRs displayed increased CB1 expression in prelimbic cortex and cingulate cortex area 1 and in CA3 region of the dorsal hippocampus. Conversely, SHRs exhibited decreases in TRPV1 expression in prelimbic and CA1 region of dorsal hippocampus and increases in the basolateral amygdala. AM404, WIN 55,212-2 and capsaicin attenuated SHRs CFC deficit, although WIN 55,212-2 worsened SHRs CFC deficit in higher doses. WRs and SHRs CFC were modulated by distinct doses, suggesting that these strains display different responsiveness to cannabinoid and vanilloid drugs. Treatment with capsazepine did not modify CFC in either strains. The effects of AM404 on SHRs CFC deficit was not blocked by pretreatment with rimonabant (CB1 antagonist) or capsazepine. These results reinforce the involvement of the endocannabinoid/endovanilloid systems in the SHRs CFC deficit and point to these systems as targets to treat the emotional processing/cognitive symptoms of schizophrenia., (Copyright © 2019. Published by Elsevier Ltd.)- Published
- 2019
- Full Text
- View/download PDF